Twist Bioscience Stock Intrinsic Value – Twist Bioscience Announces Appointment of Adam Laponis as Chief Financial Officer
January 6, 2024
🌥️Trending News
Twist Bioscience ($NASDAQ:TWST), a leader in synthetic DNA manufacturing and product development, has recently announced the appointment of Adam Laponis as their new Chief Financial Officer. Twist Bioscience is a biotechnology company that specializes in the synthesis of high-quality DNA that can be used for a variety of applications, including in biomedical research, drug discovery, and the development of industrial-scale biotechnology products. He has held numerous executive positions, including Chief Financial Officer at Forge Therapeutics and CFO at IGM Biosciences. Adam also provides guidance on financial strategy and business operations to several venture capital firms.
Adam’s knowledge and leadership will be instrumental in driving the company’s growth both domestically and internationally. His unique set of skills and expertise will help Twist Bioscience to continue delivering innovative solutions to its clients.
Stock Price
The appointment immediately took effect upon the announcement, and Mr. Laponis has already become an official member of the leadership team of the company. The announcement also had a positive effect on the stock market. TWIST BIOSCIENCE stock opened at $32.8 and closed at $34.0, representing a 1.3% increase from the previous closing price of 33.6. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Twist Bioscience. More…
| Total Revenues | Net Income | Net Margin |
| 245.11 | -204.62 | -80.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Twist Bioscience. More…
| Operations | Investing | Financing |
| -123.04 | -232.93 | 270.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 776.4 | 152.97 | 11.46 |
Key Ratios Snapshot
Some of the financial key ratios for Twist Bioscience are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.6% | – | -83.0% |
| FCF Margin | ROE | ROA |
| -67.3% | -19.3% | -16.4% |
Analysis – Twist Bioscience Stock Intrinsic Value
At GoodWhale, we have conducted an analysis of TWIST BIOSCIENCE‘s fundamentals. Our proprietary Valuation Line has calculated the intrinsic value of TWIST BIOSCIENCE stock to be around $87.1. This means that the stock is currently trading at $34.0, which is a 61.0% discount from its intrinsic value. We believe this presents an opportunity to invest in a company that is currently undervalued. More…
Peers
It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.
– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)
FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.
FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.
FoundHTG has a market cap of $6.07M and a ROE of -156.17%.
– Proteome Sciences PLC ($LSE:PRM)
Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.
– Genedrive PLC ($LSE:GDR)
Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.
Summary
Twist Bioscience, a leading synthetic DNA technology company, has recently appointed Adam Laponis as its CFO. As a financial executive, Mr. Laponis brings extensive experience in financial operations, corporate finance, and venture capital. Investors should take note of the appointment as it is an indication of the company’s ability to attract skilled talent and its commitment to sound financial management.
Twist Bioscience is well-positioned to benefit from the growing demand for synthetic DNA, which is being driven by the increased use of gene editing and targeted therapies. With Mr. Laponis at the helm, investors can expect the company to continue to pursue long-term value creation while navigating the dynamic biotech landscape.
